Andrew Abrams joined New Science Ventures in September 2016. He was formerly an Associate in J.P. Morgan’s healthcare investment banking practice in London, where he focused on mergers and acquisitions and debt and equity transactions in Europe and the U.S. He advised a wide array of clients spanning the biotechnology, pharmaceutical, medical device, diagnostic and service sub-sectors. Andrew currently serves on the Board of Directors of Paradigm Diagnostics. He holds B.A., M.A. and M.Sci. degrees in Natural Sciences and Biochemistry from the University of Cambridge and participated in Cambridge’s exchange program with the Massachusetts Institute of Technology. He also holds an M.B.A. from Harvard Business School.